Multidrug-resistant Gram-negative bacteria
From IDWiki
Revision as of 13:07, 26 August 2020 by Aidan (talk | contribs) (Created page with "== Management == * Ceftolozane-tazobactam ** * Ceftazidime-avibactam ** Special Access Program * Fosfomycin ** * Colistin ** * Cefiderocol ** Special A...")
Management
- Ceftolozane-tazobactam
- Ceftazidime-avibactam
- Special Access Program
- Fosfomycin
- Colistin
- Cefiderocol
- Special Access Program as well as preapproval by manufacturer
- Meropenem-vaborbactam
- Awaiting Health Canada Drug Review
- Imipenem-relebactam
- Really imipenem-cilastatin-relebactam
- Awaiting Health Canada Drug Review
References
- ^ A.-P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, C.G. Giske, S. Harbarth, J.F. Hindler, G. Kahlmeter, B. Olsson-Liljequist, D.L. Paterson, L.B. Rice, J. Stelling, M.J. Struelens, A. Vatopoulos, J.T. Weber, D.L. Monnet. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x.
